109 related articles for article (PubMed ID: 18289857)
1. Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template.
Spencer J; Gaffen J; Griffin E; Harper EA; Linney ID; McDonald IM; Roberts SP; Shaxted ME; Adatia T; Bashall A
Bioorg Med Chem; 2008 Mar; 16(6):2974-83. PubMed ID: 18289857
[TBL] [Abstract][Full Text] [Related]
2. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR studies of 1,3,4-benzotriazepine derivatives as CCK2 receptor antagonists.
Kaur K; Talele TT
J Mol Graph Model; 2008 Nov; 27(4):409-20. PubMed ID: 18774323
[TBL] [Abstract][Full Text] [Related]
4. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
McDonald IM; Black JW; Buck IM; Dunstone DJ; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Pether MJ; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Walker MK; Watt GF; Wright L; Wright PT; Xun W
J Med Chem; 2007 Jun; 50(13):3101-12. PubMed ID: 17536796
[TBL] [Abstract][Full Text] [Related]
5. Benzotriazonine as a new core structure for the design of CCK-receptor antagonists.
Escherich A; Escrieut C; Fourmy D; Moroder L
J Pept Sci; 1999 Mar; 5(3):155-8. PubMed ID: 10323559
[TBL] [Abstract][Full Text] [Related]
6. Toward the identification of a reliable 3D QSAR pharmacophore model for the CCK2 receptor antagonism.
Gupta AK; Varshney K; Saxena AK
J Chem Inf Model; 2012 May; 52(5):1376-90. PubMed ID: 22530718
[TBL] [Abstract][Full Text] [Related]
7. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological comparison of the alternatively spliced short and long CCK2 receptors.
Morton MF; Harper EA; Tavares IA; Shankley NP
Br J Pharmacol; 2003 Sep; 140(1):218-24. PubMed ID: 12967952
[TBL] [Abstract][Full Text] [Related]
9. Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
Low CM; Buck IM; Cooke T; Cushnir JR; Kalindjian SB; Kotecha A; Pether MJ; Shankley NP; Vinter JG; Wright L
J Med Chem; 2005 Nov; 48(22):6790-802. PubMed ID: 16250638
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Gaffen J; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Patel D; Pether MJ; Raynor M; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Wright PT; Xun W
J Med Chem; 2007 Oct; 50(20):4789-92. PubMed ID: 17850061
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis.
Rosen MD; Hack MD; Allison BD; Phuong VK; Woods CR; Morton MF; Prendergast CE; Barrett TD; Schubert C; Li L; Wu X; Wu J; Freedman JM; Shankley NP; Rabinowitz MH
Bioorg Med Chem; 2008 Apr; 16(7):3917-25. PubMed ID: 18289861
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
[TBL] [Abstract][Full Text] [Related]
13. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.
Pippel M; Boyce K; Venkatesan H; Phuong VK; Yan W; Barrett TD; Lagaud G; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2009 Nov; 19(22):6376-8. PubMed ID: 19815410
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety.
Antonelli T; Tomasini MC; Mazza R; Fuxe K; Gaetani S; Cuomo V; Tanganelli S; Ferraro L
J Pharmacol Exp Ther; 2009 May; 329(2):708-17. PubMed ID: 19197005
[TBL] [Abstract][Full Text] [Related]
16. Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
Buck IM; Black JW; Cooke T; Dunstone DJ; Gaffen JD; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Low CM; McDonald IM; Pether MJ; Roberts SP; Shankley NP; Shaxted ME; Steel KI; Sykes DA; Tozer MJ; Watt GF; Walker MK; Wright L; Wright PT
J Med Chem; 2005 Nov; 48(22):6803-12. PubMed ID: 16250639
[TBL] [Abstract][Full Text] [Related]
17. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
Pippel M; Allison BD; Phuong VK; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2009 Nov; 19(22):6373-5. PubMed ID: 19811913
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship of new 1,5-dialkyl-1,5-benzodiazepines as cholecystokinin-2 receptor antagonists.
Roberts K; Ursini A; Barnaby R; Cassarà PG; Corsi M; Curotto G; Donati D; Feriani A; Finizia G; Marchioro C; Niccolai D; Oliosi B; Polinelli S; Ratti E; Reggiani A; Tedesco G; Tranquillini ME; Trist DG; van Amsterdam FT
Bioorg Med Chem; 2011 Jul; 19(14):4257-73. PubMed ID: 21689940
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamic analysis does not allow discrimination of agonists and antagonists at human CCK2S-receptors.
Harper EA; Mitchell EA; Griffin EP; Kalindjian SB
Eur J Pharmacol; 2008 Feb; 581(1-2):1-12. PubMed ID: 18158148
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com.
Geneste H; Backfisch G; Braje W; Delzer J; Haupt A; Hutchins CW; King LL; Lubisch W; Steiner G; Teschendorf HJ; Unger L; Wernet W
Bioorg Med Chem Lett; 2006 Feb; 16(3):658-62. PubMed ID: 16271293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
